Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists
Takashi Nagahara, Tsuyoshi Saitoh, Noriki Kutsumura, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 20, pp. 7931-7937
Closed Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Narcolepsy
Birgitte Rahbek Kornum, Stine Knudsen, Hanna M. Ollila, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 240
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation
Chuan Hong, Noel Byrne, Beata Zamlynny, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 104
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models
Yoko Irukayama‐Tomobe, Yasuhiro Ogawa, Hiromu Tominaga, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 22, pp. 5731-5736
Open Access | Times Cited: 126
Hypocretin underlies the evolution of sleep loss in the Mexican cavefish
James B. Jaggard, Bethany A. Stahl, Evan Lloyd, et al.
eLife (2018) Vol. 7
Open Access | Times Cited: 111
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Orexins and stress
Laura A. Grafe, Seema Bhatnagar
Frontiers in Neuroendocrinology (2018) Vol. 51, pp. 132-145
Open Access | Times Cited: 106
Treatment Options for Narcolepsy
Lucie Barateau, Régis Lopez, Yves Dauvilliers
CNS Drugs (2016) Vol. 30, Iss. 5, pp. 369-379
Closed Access | Times Cited: 93
Recent advances in treatment for narcolepsy
Lucie Barateau, Yves Dauvilliers
Therapeutic Advances in Neurological Disorders (2019) Vol. 12
Open Access | Times Cited: 84
TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice
Hiroshi Yukitake, Tatsuhiko Fujimoto, Takashi Ishikawa, et al.
Pharmacology Biochemistry and Behavior (2019) Vol. 187, pp. 172794-172794
Closed Access | Times Cited: 83
An Updated Understanding of the Mechanisms Involved in cHemotherapy-Induced Neuropathy
Jessica A. Boyette-Davis, Saiyun Hou, Salahadin Abdi, et al.
Pain Management (2018) Vol. 8, Iss. 5, pp. 363-375
Open Access | Times Cited: 78
Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy
Steven T. Szabo, Michael J. Thorpy, Geert Mayer, et al.
Sleep Medicine Reviews (2018) Vol. 43, pp. 23-36
Open Access | Times Cited: 72
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Synthesis and Characterization of a New Carbon-11 Labeled Positron Emission Tomography Radiotracer for Orexin 2 Receptors Neuroimaging
Yanli Wang, Yongle Wang, Yan Liu, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 215-222
Open Access | Times Cited: 6
Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics
Sarah Wurts Black, Michael D. Schwartz, Tsui-Ming Chen, et al.
Biological Psychiatry (2016) Vol. 82, Iss. 9, pp. 623-633
Open Access | Times Cited: 54
Pharmacological management of narcolepsy with and without cataplexy
Ulf Kallweit, Claudio L. Bassetti
Expert Opinion on Pharmacotherapy (2017) Vol. 18, Iss. 8, pp. 809-817
Closed Access | Times Cited: 52
Challenges in the development of therapeutics for narcolepsy
Sarah Wurts Black, Akihiro Yamanaka, Thomas S. Kilduff
Progress in Neurobiology (2015) Vol. 152, pp. 89-113
Open Access | Times Cited: 50
Orexin 2 receptor regulation of the hypothalamic–pituitary–adrenal (HPA) response to acute and repeated stress
Laura A. Grafe, Darrell Eacret, Sandra Luz, et al.
Neuroscience (2017) Vol. 348, pp. 313-323
Open Access | Times Cited: 50
Differential Roles of Each Orexin Receptor Signaling in Obesity
Miyo Kakizaki, Yousuke Tsuneoka, Kenkichi Takase, et al.
iScience (2019) Vol. 20, pp. 1-13
Open Access | Times Cited: 46
Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant Orexin 2 Receptor Agonist
Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, et al.
ACS Medicinal Chemistry Letters (2022) Vol. 13, Iss. 3, pp. 457-462
Open Access | Times Cited: 26
Orexin Signaling: A Complex, Multifaceted Process
Natasha C. Dale, Daniël Hoyer, Laura H. Jacobson, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 26
Molecular mechanism of the wake-promoting agent TAK-925
Jie Yin, Yanyong Kang, Aaron P. McGrath, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Design and Synthesis of Orexin 1 Receptor-Selective Agonists
Keita Iio, Kao Hashimoto, Yasuyuki Nagumo, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 8, pp. 5453-5464
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top